Mucosolvan Schleimlöser (Ambroxol Hydrochloride)

Ambroxol stimulates the bronchial epithelium to increase surfactant production and activates lysosomal enzymes, which reduces mucus viscosity. The resulting thinner mucus is cleared more efficiently by the ciliary action of the airways, improving cough effectiveness and airway patency.

The appropriate dose of Mucosolvan Schleimlöser is determined by a qualified healthcare professional based on the patient’s age, condition severity, and overall health status. Patients should follow the prescriber’s instructions and not alter the dosage without medical advice.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using this medication.

To order Mucosolvan Schleimlöser, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Ambroxol, the active ingredient in Mucosolvan Schleimlöser, differs from agents like N‑acetylcysteine by also stimulating surfactant production and having a mild local anesthetic effect on airway nerves. Both classes reduce mucus viscosity, but ambroxol may provide faster symptom relief and is available over‑the‑counter in many EU markets.

Store Mucosolvan Schleimlöser at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed to maintain stability.

Mucosolvan Schleimlöser is taken orally, usually with a glass of water. The exact administration schedule, including frequency and duration, should be prescribed by a healthcare professional based on the individual’s clinical condition.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, life‑threatening skin conditions like Stevens‑Johnson syndrome, significant liver enzyme elevations indicating hepatic dysfunction, and hematologic abnormalities such as eosinophilia or leukopenia. Any signs of these reactions require immediate medical attention.

Individuals with known hypersensitivity to Ambroxol Hydrochloride or any excipients in the formulation should avoid this product. Patients with severe renal or hepatic impairment should use it only under close medical supervision, and those with uncontrolled asthma may need alternative therapy.